No abstract available
Plain language summary
This study uses annual Medicare Part B spending data to examine the potential savings from the drug pricing reforms in the Inflation Reduction Act of 2022.
Publication types
- Research Support, Non-U.S. Gov't
MeSH terms
- Cost Savings* / economics
- Drug Costs*
- Health Expenditures
- Inflation, Economic*
- Medicare Part B* / economics
- Medicare Part D*
- United States